文献速递乳房整形与再造显微修复重建

血管化淋巴结移植联合自体乳房再造的成本效用分析

Combining vascularized lymph node transfer with autologous breast reconstruction: A Surveillance, Epidemiology and End Results (SEER) Database cost-utility analysis.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2020-05-21

本研究采用马尔可夫模型微模拟,基于SEER数据库等数据,评估血管化淋巴结移植联合延迟自体乳房再造治疗乳腺癌相关淋巴水肿的成本效用。基础案例分析显示,联合策略的增量成本效果比为13898.76美元/QALY,低于50000美元/QALY的支付意愿阈值,提示其具有成本效果。

要点

  • 联合VLNT与延迟自体腹部乳房再造在已有淋巴水肿患者中ICER为13898.76美元/QALY。
  • 以50000美元/QALY的支付意愿阈值判断,该联合策略具有成本效果。
  • 结果为VLNT在乳腺癌不同亚群中的应用及未来临床研究提供经济学依据。

核心结论

  • 在已有淋巴水肿的患者中,将VLNT与延迟自体乳房再造联合具有成本效果。

研究设计与样本

  • 成本效用分析,采用马尔可夫模型微模拟,患者特征与预期寿命来自SEER数据库。

主要发现

  • 基础案例中,联合VLNT与延迟自体腹部乳房再造的总体ICER为13898.76美元/QALY。

关键数值与推荐

  • 以50000美元/QALY为支付意愿阈值,ICER低于该阈值视为有吸引力。
  • VLNT相对效果来自文献荟萃分析,效用值基于现有最佳文献。

临床怎么用

  • 对于已有淋巴水肿的乳腺癌患者,可考虑在延迟自体乳房再造时联合VLNT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cost effectiveness of combining vascularized lymph node transfer (VLNT) with autologous breast reconstruction has not been established. Herein we describe the use of Markov modeling to evaluate the cost utility of VLNT with delayed autologous breast reconstruction for patients with breast cancer related lymphedema (BCRL). METHODS: We conducted a cost effectiveness analysis using a Markov model with microsimulation. The characteristics and associated life expectancy of the hypothetical patients were derived from the Surveillance, Epidemiology, and End Results database. Costs of were derived from the publicly available sources and health economics literature. The utilities were based on the best available literature. The relative effectiveness of VLNT was derived from a meta-analysis of the literature. A specific strategy is considered attractive if the estimate of incremental cost effectiveness ratio (ICER) is less than the amount decision makers are willing to pay for an additional quality-adjusted life-year (QALY) gain. A baseline willingness to pay of $50,000 USD per additional QALY was used for analysis. RESULTS: The base case situation demonstrated an overall ICER of $13898.76/QALY for adding VLNT to delayed autologous abdominally based breast reconstruction in the situation where lymphedema is already present, which suggests it is cost-effective at the chosen willingness to pay. DISCUSSION: This cost-utility simulation demonstrates that it is cost effective to combine delayed breast reconstruction with VLNT in patients with existing lymphedema. This could have implications for the application of the evolving technique of VLNT in the treatment of different subpopulations of breast cancer patients, and future clinical research.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Corkum JP, Bezuhly M. Combining vascularized lymph node transfer with autologous breast reconstruction: A Surveillance, Epidemiology and End Results (SEER) Database cost-utility analysis. J Plast Reconstr Aesthet Surg. 2020. PMID: 32536463. doi:10.1016/j.bjps.2020.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。